Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.63 |
| ▸ | AR | P10275 | 7/20 | 0.49 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL568905 | 0.85 | TRPV4 (0.53) | KIF11ARTRPV4 | |
| SCHEMBL29403371 | 0.83 | KIF11 (0.50) | KIF11ARPGR | |
| SCHEMBL349356 | 0.83 | KIF11 (0.50) | KIF11ARPGR | |
| Water SCHEMBL28831861 | 0.82 | KIF11 (0.61) | KIF11ARPGRPDK2RXRA | |
| Hydrochloric Acid SCHEMBL8644024 | 0.81 | KIF11 (0.48) | KIF11ARPGR | |
| SCHEMBL397926 | 0.81 | KIF11 (0.65) | KIF11ARPGRPTPN5PDK2 | |
| SCHEMBL1011734 | 0.80 | KIF11 (0.63) | KIF11ARPGRPDK2RXRA | |
| SCHEMBL7275576 | 0.79 | KIF11 (0.63) | KIF11ARPGRPTPN5PDK2 | |
| SCHEMBL3789405 | 0.78 | KIF11 (0.48) | KIF11PGRRXRARXRBRXRG | |
| SCHEMBL29655663 | 0.77 | TDP1 (0.61) | KIF11PGRMAP4K4MMP3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824825-A4 | SUBSTITUTED PYRIDOXINES AS ANTI-PLATELET AGENTS | MEDICURE INT INC (BB) | 2009-07-08 | — | — | EP | disclosed |
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | MEDICURE INTERNATIONAL INC. (BB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | MEDICURE INTERNATIONAL INC. (BB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | MEDICURE INTERNATIONAL INC. (BB) | 2008-12-11 | — | — | US | disclosed |
| EP-1824825-A1 | SUBSTITUTED PYRIDOXINES AS ANTI-PLATELET AGENTS | Medicure International Inc. (BB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006045203-A1 | SUBSTITUTED PYRIDOXINES AS ANTI-PLATELET AGENTS | MEDICURE INTERNATIONAL INC. (CA) | 2006-05-04 | — | — | WO | disclosed |
| US-20060094749-A1 | Substituted pyridoxines as anti-platelet agents | MEDICURE INTERNATIONAL INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306108-A1 | Substituted Pyridoxines As Anti-Platelet Agents | PNPO, GP6, PFKP | KIF11 4003/4885AR 4712/4885PGR 641/4885 |
| US-20060094749-A1 | Substituted pyridoxines as anti-platelet agents | PNPO, GP6, PFKP | KIF11 4003/4885AR 4712/4885PGR 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.